Literature DB >> 26510695

Whither Anticoagulation in Pulmonary Arterial Hypertension? Conflicting Evidence REVEALed.

Robert P Frantz1.   

Abstract

Entities:  

Keywords:  Editorials; anticoagulants; hypertension, pulmonary; treatment outcome; warfarin

Mesh：

Substances：

Year:  2015        PMID： 26510695      PMCID： PMC4690770          DOI： 10.1161/CIRCULATIONAHA.115.019651

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  6 in total

1.  The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects.

Authors:  D HEATH; J E EDWARDS
Journal:  Circulation       Date:  1958-10       Impact factor: 29.690

2.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

3.  Primary pulmonary hypertension: natural history and the importance of thrombosis.

Authors:  V Fuster; P M Steele; W D Edwards; B J Gersh; M D McGoon; R L Frye
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

4.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

5.  Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Authors:  Ioana R Preston; Kari E Roberts; Dave P Miller; Ginny P Sen; Mona Selej; Wade W Benton; Nicholas S Hill; Harrison W Farber
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

6.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690
  6 in total
  2 in total

1.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.